MAI Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-198
| Closed | -$34.2K | – | 2628 |
|
|
2026
Q1 | $34.2K | Buy |
198
+80
| +68% | +$14.8K | ﹤0.01% | 2482 |
|
|
2025
Q4 | $23.5K | Buy |
118
+17
| +17% | +$3.08K | ﹤0.01% | 2428 |
|
|
2025
Q3 | $15.8K | Sell |
101
-39
| -28% | -$6.19K | ﹤0.01% | 2513 |
|
|
2025
Q2 | $21.2K | Sell |
140
-77
| -35% | -$10.3K | ﹤0.01% | 2321 |
|
|
2025
Q1 | $32.7K | Sell |
217
-170
| -44% | -$28.5K | ﹤0.01% | 1956 |
|
|
2024
Q4 | $71.4K | Buy |
+387
| New | +$74.5K | ﹤0.01% | 1589 |
|
|
2022
Q3 | – | Sell |
-5,987
| Closed | -$1.28M | – | 968 |
|
|
2022
Q2 | $1.28M | Buy |
5,987
+405
| +7% | +$99K | 0.02% | 332 |
|
|
2022
Q1 | $1.58M | Sell |
5,582
-424
| -7% | -$131K | 0.03% | 312 |
|
|
2021
Q4 | $2.26M | Sell |
6,006
-255
| -4% | -$99.1K | 0.04% | 262 |
|
|
2021
Q3 | $2.58M | Sell |
6,261
-40
| -0.6% | -$16.6K | 0.05% | 202 |
|
|
2021
Q2 | $2.33M | Buy |
6,301
+4
| +0.1% | +$1.34K | 0.05% | 217 |
|
|
2021
Q1 | $1.82M | Buy |
6,297
+38
| +0.6% | +$10.6K | 0.04% | 226 |
|
|
2020
Q4 | $1.56M | Sell |
6,259
-100
| -2% | -$23.8K | 0.04% | 237 |
|
|
2020
Q3 | $1.44M | Sell |
6,359
-767
| -11% | -$159K | 0.04% | 217 |
|
|
2020
Q2 | $1.24M | Sell |
7,126
-563
| -7% | -$89.9K | 0.04% | 238 |
|
|
2020
Q1 | $970K | Buy |
7,689
+130
| +2% | +$19.5K | 0.04% | 248 |
|
|
2019
Q4 | $1.16M | Sell |
7,559
-190
| -2% | -$26.3K | 0.04% | 257 |
|
|
2019
Q3 | $1.03M | Buy |
7,749
+103
| +1% | +$13.8K | 0.05% | 236 |
|
|
2019
Q2 | $1.08M | Sell |
7,646
-494
| -6% | -$67K | 0.05% | 235 |
|
|
2019
Q1 | $1.18M | Sell |
8,140
-747
| -8% | -$98.1K | 0.06% | 199 |
|
|
2018
Q4 | $1.01M | Sell |
8,887
-563
| -6% | -$70.5K | 0.06% | 211 |
|
|
2018
Q3 | $1.27M | Sell |
9,450
-405
| -4% | -$50K | 0.06% | 194 |
|
|
2018
Q2 | $1.11M | Sell |
9,855
-160
| -2% | -$17.3K | 0.06% | 203 |
|
|
2018
Q1 | $1.07M | Sell |
10,015
-207
| -2% | -$22.3K | 0.06% | 207 |
|
|
2017
Q4 | $1.12M | Buy |
10,222
+37
| +0.4% | +$4.03K | 0.06% | 205 |
|
|
2017
Q3 | $1.1M | Buy |
10,185
+7,756
| +319% | +$797K | 0.07% | 186 |
|
|
2017
Q2 | $246K | Sell |
2,429
-65
| -3% | -$5.98K | 0.02% | 379 |
|
|
2017
Q1 | $224K | Buy |
+2,494
| New | +$212K | 0.02% | 396 |
|
|
2016
Q4 | – | Sell |
-2,511
| Closed | -$209K | – | 445 |
|
|
2016
Q3 | $209K | Buy |
+2,511
| New | +$210K | 0.02% | 400 |
|
|
2015
Q2 | – | Sell |
-2,874
| Closed | -$228K | – | 483 |
|
|
2015
Q1 | $228K | Sell |
2,874
-644
| -18% | -$47.5K | 0.02% | 437 |
|
|
2014
Q4 | $224K | Sell |
3,518
-448
| -11% | -$28.1K | 0.02% | 421 |
|
|
2014
Q3 | $237K | Sell |
3,966
-921
| -19% | -$52.7K | 0.02% | 341 |
|
|
2014
Q2 | $262K | Buy |
4,887
+583
| +14% | +$32K | 0.03% | 323 |
|
|
2014
Q1 | $260K | Buy |
4,304
+283
| +7% | +$16.5K | 0.03% | 327 |
|
|
2013
Q4 | $213K | Buy |
+4,021
| New | +$202K | 0.02% | 345 |
|
Other funds holding CRL
AI
MAI Capital Management's CRL Position: Q2 2026 in Review
MAI Capital Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 198 shares — an estimated $34.2K sold.
MAI Capital Management first reported a position in CRL in Q4 2013 and held it in 35 quarters. The position peaked at $2.58M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- MAI Capital Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
- MAI Capital Management sold 198 Charles River Laboratories shares in Q2 2026, an estimated $34.2K.
- MAI Capital Management first reported a position in Charles River Laboratories in Q4 2013 and held it in 35 quarters.
- MAI Capital Management's Charles River Laboratories position peaked at $2.58M in Q3 2021.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.